26251cd8-7e90-46bb-a025-1328d83c83ee
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.350
- XENOBIOTIC_METABOLISM+0.340
- APICAL_SURFACE+0.330
- APICAL_JUNCTION+0.320
- PANCREAS_BETA_CELLS+0.320
- NOTCH_SIGNALING+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- CHOLESTEROL_HOMEOSTASIS+0.270
- ESTROGEN_RESPONSE_EARLY+0.260
- MYOGENESIS+0.260
Top 10 suppressed
- PROTEIN_SECRETION-0.360
- G2M_CHECKPOINT-0.220
- ANDROGEN_RESPONSE-0.210
- E2F_TARGETS-0.200
- UV_RESPONSE_DN-0.150
- MITOTIC_SPINDLE-0.070
- ALLOGRAFT_REJECTION-0.060
- MYC_TARGETS_V1-0.030
- SPERMATOGENESIS-0.030
- HYPOXIA-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 05167d53-0b47-4131-bfa4-450b236b9fd5 | — | — | 0.893 |
| 2 | b83a1cf6-50a6-44fa-834d-8b3df88149fa | — | — | 0.861 |
| 3 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.838 |
| 4 | bb3dc2ff-a686-483e-8d3c-e06649462881 | — | — | 0.795 |
| 5 | SAMN03290915 | — | — | 0.787 |
| 6 | d496ef4f-4716-4e6e-94e3-fce93b26d4ee | — | — | 0.773 |
| 7 | 290b89f5-2a44-424b-b77d-a190dcb93e07 | — | — | 0.760 |
| 8 | a4322796-9189-48c2-9e7c-7b1493b5799a | — | — | 0.760 |
| 9 | 8f45c6c4-b98d-4e0b-9bb0-b5be3894076d | — | — | 0.757 |
| 10 | a8235ad1-0c5f-4a0b-b595-85ef3a1e49ff | — | — | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.340 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |